Results 11 to 20 of about 6,220 (214)

Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing [PDF]

Clinical Pharmacology & Therapeutics, 2011
Thiopurine methyltransferase (TPMT) activity exhibits monogenic co-dominant inheritance, with ethnic differences in the frequency of occurrence of variant alleles. With conventional thiopurine doses, homozygous TPMT-deficient patients (~1 in 178 to 1 in 3,736 individuals with two nonfunctional TPMT alleles) experience severe myelosuppression, 30-60% of
Relling, M V, Gardner, E E, Sandborn, W J, Schmiegelow, K, Pui, C-H, Yee, S W, Stein, Paul C., Carrillo, Maria Berrocal, Evans, W E, Klein, T E   +9 more
openaire   +5 more sources

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update. [PDF]

Clin Pharmacol Ther
Thiopurine methyltransferase (TPMT) and Nudix hydrolase 15 (NUDT15) are key enzymes that catabolize thiopurines. Decreased or no‐function alleles in TPMT and NUDT15 are associated with reduced or no enzyme activity and predictive of pronounced adverse effects, including severe myelosuppression, that may occur among individuals treated with standard ...
Maillard M, Schwab M, Whirl-Carrillo M, Moyer AM, Suarez-Kurtz G, Pui CH, Stein CM, Klein TE, Spahn C, Kwon S, Hartono JL, de Boer NK, Ahmad T, Antillon-Klussmann FG, Caudle KE, Kato M, Yeoh AEJ, Schmiegelow K, Yang JJ.   +18 more
europepmc   +2 more sources

Pharmacogenomics of Thiopurine Drugs: A Bench-To-Bedside Success Story in Thailand. [PDF]

Clin Transl Sci
ABSTRACT Thiopurine drugs are the cornerstone treatment for many diseases such as acute lymphoblastic leukemia (ALL), organ rejection, inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and other autoimmune diseases.
Biswas M, John S, Murad MA, Sukasem C.
europepmc   +2 more sources

Genetic Determinants of Hematopoietic Toxicity Risk in Thai Pediatric Patients Undergoing 6-Mercaptopurine Treatment. [PDF]

Clin Transl Sci
ABSTRACT The nucleoside diphosphate‐linked moiety X‐type motif 15 (NUDT15) has been identified as a key genetic determinant of 6‐mercaptopurine (6‐MP)‐induced hematopoietic toxicity in populations with a high frequency of NUDT15 variants but a low frequency of thiopurine S‐methyltransferase (TPMT) variants.
Khaeso K, Chainansamit SO, Kuwatjanakul P, Komvilaisak P, Nakkam N, Suwannaying K, Vannaprasaht S, Dornsena A, Tassaneeyakul W.   +8 more
europepmc   +2 more sources

gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel disease [PDF]

Intestinal Research, 2020
Thiopurine has been used to maintain remission and to reduce antidrug antibody formation in monoclonal antibody therapy in patients with inflammatory bowel disease (IBD). The use of thiopurine is limited by side effects such as leukopenia.
Katsuyoshi Matsuoka
doaj   +1 more source

Association between thiopurine S-methyltransferase polymorphisms and thiopurine-induced adverse drug reactions in patients with inflammatory bowel disease: a meta-analysis. [PDF]

PLoS ONE, 2015
Thiopurine drugs are well established treatments in the management of inflammatory bowel disease (IBD), but their use is limited by significant adverse drug reactions (ADRs).
Yue-Ping Liu, Hai-Yan Wu, Xiang Yang, Han-Qing Xu, Yong-Chuan Li, Da-Chuan Shi, Jun-Fu Huang, Qing Huang, Wei-Ling Fu   +8 more
doaj   +1 more source

Optimizing thiopurine therapy in children with acute lymphoblastic leukemia: A promising “MINT” sequencing strategy and therapeutic “DNA-TG” monitoring

Frontiers in Pharmacology, 2022
Thiopurines, including thioguanine (TG), 6-mercaptopurine (6-MP), and azathioprine (AZA), are extensively used in clinical practice in children with acute lymphoblastic leukemia (ALL) and inflammatory bowel diseases.
Hong-Li Guo, Yue-Tao Zhao, Yue-Tao Zhao, Wei-Jun Wang, Wei-Jun Wang, Na Dong, Na Dong, Ya-Hui Hu, Yuan-Yuan Zhang, Feng Chen, Li Zhou, Tao Li   +11 more
doaj   +1 more source

Unraveling Novel Genetic Determinants of Thiopurine Response Via TWAS. [PDF]

Clin Pharmacol Ther
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Thiopurines such as 6‐mercaptopurine (6MP) are essential in ALL maintenance therapy. However, dose‐limiting toxicities can significantly disrupt treatment. While genetic variants in TPMT and NUDT15 are known to affect thiopurine response, many patients with normal function ...
Bidoli C, Yang W, Karol SE, Lucafò M, Stocco G, Yang JJ.   +5 more
europepmc   +2 more sources

TPMT and NUDT15 polymorphisms in thiopurine induced leucopenia in inflammatory bowel disease: a prospective study from India

BMC Gastroenterology, 2021
Background Polymorphisms in thiopurine methyltransferase (TPMT) and Nudix hydrolase-15 (NUDT15) have been implicated as the predominant cause of thiopurine induced leukopenia in the Western countries and East Asia respectively.
Narinder Grover, Prateek Bhatia, Antriksh Kumar, Minu Singh, Deepesh Lad, Harshal S. Mandavdhare, Jayanta Samanta, Kaushal K. Prasad, Usha Dutta, Vishal Sharma   +9 more
doaj   +1 more source

Economic evaluations of pharmacogenetic and pharmacogenomic screening tests : a systematic review : second update of the literature [PDF]

, 2016
Objective : Due to extended application of pharmacogenetic and pharmacogenomic screening (PGx) tests it is important to assess whether they provide good value for money. This review provides an update of the literature. Methods : A literature search was
Annemans, Lieven, Berm, Elizabeth JJ, Boersma, Cornelis, de Looff, Margot, Postma, Maarten J, van Boven, Job FM, Vegter, Stefan, Wilffert, Bob   +7 more
core   +9 more sources